interstitial pulmonary disease :: Article Creator Trevi Therapeutics To Participate In Upcoming August Conferences NEW HAVEN, Conn., July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following conferences in August. Trevi Therapeutics, Inc. Www.Trevitherapeutics.Com (PRNewsfoto/Trevi Therapeutics, Inc.) Oppenheimer's 2025 Biotech in the BerkshiresAugust 4 – 6, 2025, Berkshires, MassachusettsTrevi Representative: Jennifer Good, President and CEO Stifel's 2025 Biotech Summer SummitAugust 11 – 13, 2025, Newport, ...